Business Context and Reporting Period
This Form 8-K was filed by Tivic Health Systems, Inc. (Nasdaq: TIVC), although the request metadata identifies the company as Valion Bio, Inc. The report concerns management changes effective April 28, 2023; it was signed and filed on May 1, 2023. Tivic is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market.
Key Financial and Operating Information
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
- Former CFO Veronica Cai is entitled to a lump-sum cash payment of $125,000, less applicable withholdings, subject to execution and non-revocation of a waiver and release of claims.
- Interim CFO Kimberly Bambach will be compensated at $200 per hour under an expected consulting agreement.
Material Changes Versus the Prior Comparable Period
- Veronica Cai resigned as Chief Financial Officer on April 28, 2023. The resignation was stated to reflect the Company’s evolving needs and not a disagreement regarding operations, policies, or practices.
- Ms. Cai’s employment agreement, dated April 1, 2022, terminated on the separation date.
- Kimberly Bambach was appointed interim Chief Financial Officer and Principal Financial and Principal Accounting Officer, serving as a non-employee consultant.
- The Company also announced an engagement of a strategic advisor to its board in a related May 1 press release, but the provided filing text does not identify the advisor or describe the engagement terms.
Guidance, Outlook, Risks, and Unusual Items
- No financial guidance or operating outlook is provided.
- The Company expects to enter into a consulting agreement with Ms. Bambach; the final agreement and any additional terms were not included in the provided text.
- The $125,000 separation payment is a material cash obligation associated with the CFO transition.
- The filing contains customary warnings that forward-looking statements are subject to risks and uncertainties and that actual results may differ materially from expectations.
- The filing states that Ms. Bambach has no reportable related-person transactions, no family relationships with Company directors or executive officers, and no arrangement with another person concerning her appointment.
Facts Investors Should Verify
- Confirm the correct issuer, because the filing identifies Tivic Health Systems, Inc., while the request metadata identifies Valion Bio, Inc.
- Review the final consulting agreement with Ms. Bambach, including scope, duration, termination provisions, and total expected compensation.
- Verify payment of the $125,000 separation amount and any related accounting or cash-flow impact.
- Review Exhibit 99.1 for details regarding the strategic advisor and other management changes.
- Consult subsequent filings for the appointment of a permanent CFO and updated liquidity, financing, and operating information.